After digging into many of the companies developing a soft tissue surgical system that may be viewed as competitive to Intuitive Surgical's da Vinci family, Piper Jaffray analyst Matt O'Brien does not believe any of the new systems will meaningfully impact Intuitive Surgical's ability to place robots or perform cases in 2018 or 2019. The analyst says he would not be surprised to see a bit of pricing pressure materialize on Intuitive starting in 2019 and have more impact in 2020, which he believes "could impact results somewhat." O'Brien expects volatility around the stock as the approval/expanded indications occur, but he doubts the news will "severely derail the name in the near term." The analyst keeps a Neutral rating on Intuitive Surgical with a $405 price target.